Učitavanje...

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellul...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Mol Hepatol
Glavni autori: Dika, Imane El, Abou-Alfa, Ghassan K.
Format: Artigo
Jezik:Inglês
Izdano: The Korean Association for the Study of the Liver 2017
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5760005/
https://ncbi.nlm.nih.gov/pubmed/29151326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2017.0108
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!